This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2004 by Trimeris.
Recruitment status was:  Active, not recruiting
Information provided by:
Trimeris Identifier:
First received: October 28, 2002
Last updated: June 23, 2005
Last verified: July 2004
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

Condition Intervention Phase
HIV Infections Drug: T-1249 Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Trimeris:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completion T1249-102;
  • Currently failing a T-20 containing regimen

Exclusion Criteria:

  • Non-completion of T1249-102.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00048217

United States, North Carolina
Durham, North Carolina, United States, 27707
Sponsors and Collaborators
  More Information Identifier: NCT00048217     History of Changes
Other Study ID Numbers: T1249-105
Study First Received: October 28, 2002
Last Updated: June 23, 2005

Keywords provided by Trimeris:
Treatment Experienced

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases processed this record on September 21, 2017